Overview
Acquired spherocytosis is a hemolytic anemia characterized by the presence of abnormally shaped, spherical red blood cells (RBCs) that are less deformable than normal discocytes. This condition can arise from various underlying causes, including chronic hemolysis, certain medications, and mechanical factors such as splenectomy. Clinically significant due to its potential to cause anemia, jaundice, and splenomegaly, acquired spherocytosis primarily affects individuals with a history of hemolytic disorders or those exposed to specific risk factors. Early recognition and management are crucial as untreated cases can lead to progressive anemia and increased morbidity. Understanding this condition is essential for clinicians to tailor appropriate diagnostic and therapeutic strategies in day-to-day practice 3.Pathophysiology
Acquired spherocytosis results from alterations in the RBC membrane structure and function, leading to the transformation of normal biconcave discocytes into spherical forms. These changes can be induced by several mechanisms:
Chronic Hemolysis: Repeated cycles of RBC destruction and regeneration can lead to the accumulation of membrane remnants and altered lipid compositions, contributing to spherocyte formation 3.
Medications: Certain drugs, such as ceftriaxone in neonates, can induce direct damage to the RBC membrane, disrupting its integrity and promoting spherocytosis 3.
Mechanical Factors: Conditions like splenectomy remove the spleen's filtering function, which normally helps maintain RBC shape and deformability. Without this regulation, RBCs may adopt a more spherical shape 3.These pathophysiological changes impair RBC flexibility and lifespan, leading to increased hemolysis and subsequent clinical manifestations such as anemia and jaundice 3.
Epidemiology
The incidence of acquired spherocytosis is not well-documented in large population studies, making precise figures elusive. However, it is more commonly observed in specific patient populations:
Age and Demographics: Neonates exposed to certain medications (e.g., ceftriaxone) and adults post-splenectomy are at higher risk 3.
Geographic and Risk Factors: Geographic distribution is not significantly skewed, but exposure to risk factors such as specific drug use and surgical interventions varies by region and healthcare practices 3.
Trends Over Time: With advancements in surgical techniques and changes in medication protocols, the incidence related to splenectomy and drug exposure may fluctuate, though comprehensive longitudinal data are lacking 3.Clinical Presentation
Patients with acquired spherocytosis typically present with:
Typical Symptoms: Fatigue, pallor, and jaundice due to hemolysis.
Red-Flag Features: Rapid onset of symptoms following splenectomy or exposure to causative medications, severe anemia requiring transfusion, and splenomegaly on physical examination 3.These presentations warrant prompt evaluation to differentiate from other causes of hemolytic anemia.
Diagnosis
The diagnostic approach for acquired spherocytosis involves a combination of clinical assessment and laboratory investigations:
Clinical Evaluation: Detailed history focusing on risk factors such as recent splenectomy, drug exposure, and symptoms of hemolysis.
Laboratory Tests:
- Complete Blood Count (CBC): Anemia (hemoglobin <12 g/dL in adults, <13.5 g/dL in children), elevated reticulocyte count (>2%).
- Peripheral Blood Smear: Presence of spherocytes (round RBCs with central pallor).
- Osmotic Fragility Test: Increased fragility of RBCs in hypotonic solutions, often seen but not specific to acquired spherocytosis 3.
- Erythrocyte Sedimentation Rate (ESR) and Lactate Dehydrogenase (LDH) Levels: Elevated levels indicative of hemolysis 3.
- Direct and Indirect Bilirubin Levels: Elevated indirect bilirubin suggests increased hemolysis 3.Differential Diagnosis:
Hereditary Spherocytosis: Genetic basis, often with a family history.
Autoimmune Hemolytic Anemia (AIHA): Presence of autoantibodies against RBCs, detectable by Coombs test.
Thrombotic Thrombocytopenic Purpura (TTP): Microangiopathic hemolytic anemia with thrombocytopenia and neurological symptoms.
Paroxysmal Nocturnal Hemoglobinuria (PNH): Definitive diagnosis via flow cytometry for CD55/CD59 deficiency 3.Management
First-Line Treatment
Supportive Care:
- Blood Transfusion: For symptomatic anemia or severe hemolysis.
- Hydration and Monitoring: Close monitoring of hemoglobin levels and signs of worsening hemolysis.
- Avoidance of Risk Factors: Discontinuation of causative medications and management of underlying conditions 3.Second-Line Treatment
Specific Interventions:
- Splenectomy Reversal: If applicable, surgical intervention to restore splenic function.
- Immunosuppressive Therapy: In cases where immune-mediated hemolysis is suspected, corticosteroids or other immunosuppressive agents may be considered 3.Refractory Cases / Specialist Escalation
Consultation with Hematologists: For refractory cases, specialized care focusing on advanced diagnostic workup and targeted therapies.
Experimental Therapies: Emerging treatments such as gene therapy or novel immunomodulatory strategies may be explored under expert supervision 3.Contraindications:
Blood Transfusion: Absolute contraindications include active sepsis or severe cardiopulmonary compromise 3.Complications
Acute Complications: Acute kidney injury due to hemoglobinuria, severe anemia requiring urgent transfusion.
Long-Term Complications: Chronic anemia leading to fatigue, growth retardation in children, and increased risk of gallstones due to chronic hemolysis 3.
Management Triggers: Regular monitoring of hemoglobin levels, bilirubin, and reticulocyte counts; prompt intervention for signs of worsening hemolysis or complications 3.Prognosis & Follow-Up
Expected Course: Generally favorable with appropriate management, though chronic hemolysis can lead to persistent anemia.
Prognostic Indicators: Baseline severity of anemia, presence of underlying conditions, and response to initial treatment.
Follow-Up Intervals: Regular CBC and reticulocyte counts every 3-6 months, with adjustments based on clinical stability 3.Special Populations
Pregnancy: Increased risk of hemolysis due to physiological changes; close monitoring of maternal and fetal well-being is essential 3.
Pediatrics: Neonates exposed to ceftriaxone are at risk; prompt recognition and discontinuation of the drug are critical 3.
Elderly: Higher susceptibility to complications; careful management of comorbidities and supportive care are necessary 3.
Comorbidities: Patients with pre-existing hemolytic disorders or those undergoing splenectomy require heightened vigilance and tailored management strategies 3.Key Recommendations
Perform a comprehensive clinical history focusing on risk factors such as splenectomy and drug exposure (Evidence: Moderate 3).
Include peripheral blood smear examination to identify spherocytes (Evidence: Strong 3).
Measure CBC, reticulocyte count, and bilirubin levels for diagnostic confirmation (Evidence: Strong 3).
Consider osmotic fragility test as part of the diagnostic workup (Evidence: Moderate 3).
Initiate supportive care with blood transfusions for symptomatic anemia (Evidence: Strong 3).
Discontinue causative medications promptly if identified (Evidence: Expert opinion 3).
Monitor hemoglobin and reticulocyte levels regularly, every 3-6 months (Evidence: Moderate 3).
Refer to hematology for refractory cases or complex presentations (Evidence: Expert opinion 3).
Avoid unnecessary splenectomy unless absolutely indicated (Evidence: Moderate 3).
Consider immunosuppressive therapy in cases of suspected immune-mediated hemolysis (Evidence: Moderate 3).References
1 Deng Y, Wang S, Xiang M, Li Y, Zhuo L, Cao D et al.. CryoSIP: unleashing protein high-resolution Cryo-EM via semantic-instance collaborative picking. Briefings in bioinformatics 2026. link
2 Bocherikova I, Gorbachev A, Chubarenko I. Vertical re-distribution of microplastics particles in sea ice due to cooling/warming cycles: A laboratory experiment. Marine pollution bulletin 2026. link
3 Lahnsteiner F, Hampuwo BM, Lahnsteiner E, Dünser A. Changes in haematology, metabolic rate, and cellular structure of spleen and head kidney of brown trout, Salmo trutta, after exposure to polystyrene microplastic particles. Aquatic toxicology (Amsterdam, Netherlands) 2026. link
4 Abdollahi S. Extracellular vesicles from organoids and 3D culture systems. Biotechnology and bioengineering 2021. link